[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Capricor Therap (CAPR)

Capricor Therap (CAPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 242,651
  • Shares Outstanding, K 57,912
  • Annual Sales, $ 0 K
  • Annual Income, $ -105,040 K
  • EBIT $ -120 M
  • EBITDA $ -118 M
  • 60-Month Beta 0.42
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.36

Options Overview Details

View History
  • Implied Volatility 257.43% (-45.25%)
  • Historical Volatility 318.71%
  • IV Percentile 80%
  • IV Rank 49.47%
  • IV High 456.20% on 12/02/25
  • IV Low 62.85% on 01/22/26
  • Expected Move (DTE 20) 1.68 (43.71%)
  • Put/Call Vol Ratio 0.97
  • Today's Volume 15,013
  • Volume Avg (30-Day) 11,812
  • Put/Call OI Ratio 0.42
  • Today's Open Interest 189,215
  • Open Int (30-Day) 123,445
  • Expected Range 2.17 to 5.53

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.58
  • Number of Estimates 5
  • High Estimate $-0.47
  • Low Estimate $-0.63
  • Prior Year $-0.57
  • Growth Rate Est. (year over year) -1.75%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.96 +30.07%
on 07/30/26
24.57 -84.33%
on 07/02/26
-20.23 (-84.01%)
since 06/30/26
3-Month
2.96 +30.07%
on 07/30/26
34.50 -88.84%
on 05/06/26
-29.73 (-88.53%)
since 04/30/26
52-Week
2.96 +30.07%
on 07/30/26
40.37 -90.46%
on 12/03/25
-4.33 (-52.93%)
since 07/30/25

Most Recent Stories

More News
Shareholder Alert - Robbins LLP Informs Investors of the Capricor Therapeutics, Inc. Class Action Lawsuit

Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Capricor Therapeutics, Inc. (NASDAQ: CAPR)...

CAPR : 3.85 (-8.11%)
Capricor Therapeutics, Inc. Notice of September 28, 2026 Application Deadline for Class Action Lawsuit - Contact Lewis Kahn, Esq. at Kahn Swick & Foti, LLC, Before Application Deadline

Kahn Swick & Foti , LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., notifies investors in Capricor Therapeutics, Inc. (“Capricor”...

CAPR : 3.85 (-8.11%)
CAPR Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Capricor (CAPR)

The investigation centers on Capricor's market reaction after FDA staff briefing documents challenged Deramiocel's cardiac endpoint and noted a post-randomization change to the trial's statistical analysis...

CAPR : 3.85 (-8.11%)
Law Offices of Howard G. Smith Encourages Capricor Therapeutics, Inc. (CAPR) Shareholders To Inquire About Securities Fraud Class Action

Law Offices of Howard G. Smith announces that a class action lawsuit has been filed on behalf of investors who purchased Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: ...

CAPR : 3.85 (-8.11%)
CAPR CLASS ACTION NOTICE: The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Capricor Therapeutics, Inc.

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned Nkamga v. Capricor...

CAPR : 3.85 (-8.11%)
CAPR CLASS ACTION NOTICE: Glancy Prongay Wolke & Rotter LLP Files Securities Fraud Lawsuit on Behalf of Capricor Therapeutics, Inc.

Glancy Prongay Wolke & Rotter LLP (“GPWR”) announces that it has filed a class action lawsuit in the United States District Court for the Southern District of California, captioned ...

CAPR : 3.85 (-8.11%)
CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Investigation Opened Following Massive Stock Crash

SAN FRANCISCO , July 30, 2026 /PRNewswire/ -- Hagens Berman encourages investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR)  who suffered substantial losses to submit your losses now...

CAPR : 3.85 (-8.11%)
CAPR Stock Drop Alert: Capricor Therapeutics Stock Plummets Over 64% After FDA Briefing Documents Raise Concerns, Triggering Securities Fraud Investigation by BFA Law

BFA Law is investigating whether Capricor Therapeutics, Inc. committed securities fraud relating to statements concerning Deramiocel and the integrity of the clinical data supporting its Biologics License...

CAPR : 3.85 (-8.11%)
Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws...

CAPR : 3.85 (-8.11%)
CAPR SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving Capricor

Capricor investors lost 60% to 70% after FDA briefing documents raised significant concerns regarding Deramiocel, following earlier Company statements that the FDA had not identified material review...

CAPR : 3.85 (-8.11%)

Business Summary

Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based...

See More

Key Turning Points

3rd Resistance Point 5.27
2nd Resistance Point 4.96
1st Resistance Point 4.41
Last Price 3.85
1st Support Level 3.55
2nd Support Level 3.24
3rd Support Level 2.69

See More

52-Week High 40.37
Fibonacci 61.8% 26.08
Fibonacci 50% 21.66
Fibonacci 38.2% 17.25
Last Price 3.85
52-Week Low 2.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.